Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04759781 · ClinicalTrials.gov registry record
MElanoma Research Lymph Node Prediction Implementation National_001
A clinical trial of Melanoma, sponsored by SkylineDx.
- Active
- Registry status
- 1,820
- Enrollment target
- 9
- Study locations
NCT04759781 is a study of Melanoma that is active but no longer recruiting, run by SkylineDx. The registered enrollment target is 1,820 participants, above the 700-participant average among 266 other Melanoma trials with a reported enrollment target (160% higher). The trial reports 9 study locations across 8 states.
The verdict
NCT04759781, a study of Melanoma, is active but no longer recruiting, sponsored by SkylineDx.
- ACTIVE NOT RECRUITING
- Registry status
- 1,820 participants
- Enrollment target
- 9
- Study locations
Study Summary
MERLIN\_001 is a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and to determine its prognostic value for more accurate staging of SN-negative melanoma patients.
Conditions Studied
Study Locations (9)
Kentucky
- University of Kentucky - Lexington
- University of Louisville - Louisville
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Emory University School of Medicine - Atlanta
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Mayo Clinic - Rochester
New York
- Memorial Sloan Kettering Cancer Center - New York
North Carolina
- Duke University - Durham
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,820 participants |
| Start Date | 2021-08-25 |
| Est. Completion | 2029-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04759781
The ClinicalTrials.gov registry entry for NCT04759781 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 1,820 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 700-participant average among 266 other Melanoma trials with a reported enrollment target (160% higher). The listed sponsor is SkylineDx, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT04759781 reports 9 study locations spanning 8 distinct geographic areas - top geographies include Kentucky, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT04759781 about?
NCT04759781 is a clinical study titled "MElanoma Research Lymph Node Prediction Implementation National_001". MERLIN\_001 is a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and to determine its prognostic value for more accurate staging of SN-negative melanoma patients.
What is the current status of trial NCT04759781?
This trial is currently active not recruiting. The enrollment target is 1,820 participants. The study started on 2021-08-25. Estimated completion is 2029-06.
What conditions does trial NCT04759781 study?
This clinical trial studies the following conditions: Melanoma.
Who is sponsoring clinical trial NCT04759781?
This trial is sponsored by SkylineDx, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04759781 being conducted?
This trial has 9 study locations across Florida, Georgia, Kentucky, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
RECRUITING · NA
-
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
RECRUITING · Phase 2
-
Dabrafenib and/or Trametinib Rollover Study
RECRUITING · Phase 4
-
Neoadjuvant Immune Checkpoint Blockade + a Prebiotic Food-enriched Dietary Intervention to Optimize Immune Response in Melanoma: NEO-PreFED
RECRUITING · Phase 2
-
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
RECRUITING · Phase 1
-
A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.